A host-guest complex for treating platinum-resistant ovarian cancer and its preparation method and application

Through the host-guest complex composed of calaromatic hydrocarbons and chemotherapy drugs, the programmatic necrosis pathway targets platinum-resistant ovarian cancer, solving the problem of insufficient chemotherapy resistance and diagnostic sensitivity of ovarian cancer, and achieving platinum-resistant ovarian cancer Effective treatment.

CN118320131BActive Publication Date: 2024-11-19THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY (GUANGZHOU SEVERE MATERNAL TREATMENT CENTER GUANGZHOU ROUJI HOSPITAL)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410502194.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-20
Publication Date
2024-11-19
Estimated Expiration
2044-04-20

AI Technical Summary

Technical Problem

Chemotherapy resistance of ovarian cancer leads to reduced therapeutic effects, the existing diagnosis and treatment methods have limited sensitivity and specificity for early ovarian cancer, and there is a lack of effective treatment options for platinum-resistant ovarian cancer.

Method used

A host-guest complex composed of calaromatic compounds and chemotherapeutic drugs (such as cisplatin) is used to form a complex that can kill platinum-resistant ovarian cancer cells under the programmed necrosis pathway through specific molar concentration ratios and preparation methods.

Benefits of technology

This complex is basically non-toxic to normal human cells, and can specifically kill platinum-resistant ovarian cancer cells, overcome tumor resistance, and achieve targeted treatment, and has good clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118320131B_ABST
    Figure CN118320131B_ABST
Patent Text Reader

Abstract

The present invention provides a host-guest complex and a preparation method thereof, as well as their application in treating platinum-resistant ovarian cancer. The host compound and the guest compound are prepared by a specific method at a specific ratio to prepare the host-guest complex, and the prepared host-guest complex has the characteristics of being basically non-toxic to normal human cells but being able to specifically kill platinum-resistant ovarian cancer. It is further found that the host-guest complex prepared by the present invention can overcome tumor resistance through the programmed necrosis pathway, achieve targeted treatment of resistant tumors or resistant cancers, and has good clinical application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and in particular relates to a host-guest complex and a preparation method thereof, as well as applications of the same in treating platinum-resistant ovarian cancer. Background Art

[0002] Ovarian cancer is one of the deadliest cancers of the female reproductive system, and its diagnosis and treatment face many challenges. Ovarian cancer ranks high among female cancer mortality rates worldwide. Due to the lack of obvious early symptoms and effective screening methods, most ovarian cancer patients are already in the late stage when diagnosed, which significantly affects treatment outcomes and survival rates. The five-year survival rate of patients with early-stage ovarian cancer is relatively high, but for patients with advanced ovarian cancer, this rate drops significantly.

[0003] The early symptoms of ovarian cancer are often very general and non-specific, such as abdominal distension, frequent urination, abdominal pain, indigestion, etc. These symptoms are often ignored or misdiagnosed as more common non-fatal diseases. Currently, the diagnosis of ovarian cancer mainly relies on imaging examinations (such as ultrasound, CT and MRI scans) and tumor markers (such as CA-125), but these methods have limited sensitivity and specificity for early ovarian cancer.

[0004] Treatment of ovarian cancer usually includes surgery and chemotherapy. For most patients with ovarian cancer, surgery is the preferred treatment method, which includes removing as much of the tumor as possible (called "cytoreduction") and evaluating the extent of the spread of the lesion. After surgery, most patients need to receive chemotherapy to eliminate residual cancer cells. Chemotherapy usually uses platinum drugs and paclitaxel. For specific genetic backgrounds (such as BRCA mutation carriers), PARP inhibitors can be used for treatment. In addition, immune checkpoint inhibitors have also shown therapeutic potential in some trials in recent years.

[0005] Cisplatin (DDP) is a widely used chemotherapy drug. It belongs to the platinum compound and has become an important component of the treatment of various cancers since it was approved by the FDA in 1978. The main mechanism of action of cisplatin is to form crosslinks with DNA to prevent DNA replication and transcription. It can form crosslinks between the inner and interstrands of DNA, which will cause the DNA double helix structure to distort, thereby hindering DNA synthesis and cell division, and ultimately inducing apoptosis to kill cancer cells.

[0006] Cisplatin is used to treat many types of cancer, including but not limited to: ovarian cancer, bladder cancer, testicular cancer, neck and head cancer, small cell lung cancer and non-small cell lung cancer, gastric cancer, etc. The application of cisplatin in the treatment of ovarian cancer is one of its most important clinical uses. As an effective platinum drug, cisplatin is of key significance in the treatment of ovarian cancer.

[0007] Chemoresistance in ovarian cancer is a major challenge in treatment and has a significant impact on patient prognosis and survival. Like many chemotherapy drugs, the use of cisplatin may cause tumor cells to develop resistance. Ovarian cancer patients usually respond well to initial chemotherapy, especially with platinum drugs (such as cisplatin or carboplatin) and drugs such as paclitaxel. However, many patients develop resistance after treatment, resulting in cancer recurrence and increasingly poor response to subsequent treatments.

[0008] Calixarene is a class of synthetic macrocyclic compounds, primarily synthesized from phenol and formaldehyde via condensation reactions. The name comes from the Greek word "calix," meaning "cup-shaped," because the structure of these molecules resembles a cup or funnel that can be used to "catch" other molecules. Calixarene has a wide range of applications in chemical sensing, drug delivery, catalysis, and environmental science due to their unique structure and ability to form host-guest complexes with other molecules through molecular recognition. This class of compounds is highly chemically tunable, and their properties and functions can be adjusted by varying the size of the ring, the functional groups on the rim of the cup, and other structural parameters.

[0009] The application of calixarene in the pharmaceutical field is mainly reflected in their encapsulation properties and ability to recognize specific guest molecules at the molecular level. These properties make them useful in many aspects, including:

[0010] 1. Drug delivery system: Calixarene can encapsulate drug molecules through its unique cavity structure, thus being used as a targeted delivery system. This encapsulation helps improve the solubility and bioavailability of drugs, while reducing the side effects of drugs and achieving the goal of more precise drug delivery to specific body locations.

[0011] 2. Controlled release technology: The structure of calixarene can be designed to be sensitive to environmental changes (such as pH, temperature, ionic strength, etc.), allowing it to release encapsulated drugs under specific conditions. This property makes calixarene an ideal choice for preparing controlled release drug formulations.

[0012] 3. Improve drug stability: For drugs that are easily degraded or unstable, calixarene can protect the drugs from damage by the external environment, such as oxygen, light and humidity, through encapsulation, thereby extending the shelf life of the drugs.

[0013] 4. Formation of drug complexes: Calixarenes can form non-covalent host-guest complexes with specific drug molecules. This complex form can be used to improve the physicochemical properties of drugs, such as solubility and stability, and also help change the absorption and metabolic dynamics of drugs.

[0014] 5. Biorecognition and sensor development: In the biomedical field, calixarene can also be used as a component of biosensors for detecting and identifying biomarkers, which is extremely important for disease diagnosis and treatment monitoring.

[0015] Through these applications, calixarenes provide a highly customizable and flexible platform in drug design and development, aiding the development of new drugs and improving the performance of existing drugs.

[0016] The application of calixarene in anti-tumor therapy demonstrates their potential in modern pharmacology. Calixarene can be used to encapsulate anti-cancer drugs and introduce targeting ligands (such as antibodies, small molecule targeting agents, etc.) by modifying its peripheral structure, so that the drugs can be delivered directly to cancer cells. This approach helps to increase the concentration of drugs at the tumor location and reduce the toxic effects on normal cells. The structure of calixarene can be designed to respond to specific biomarkers, such as the low pH value, hydrogen peroxide level or activity of specific enzymes that are unique to the tumor microenvironment. This allows calixarene to release drugs when they reach tumor cells, thereby improving the targeting and efficiency of treatment. Calixarene is able to encapsulate multiple drugs and support the implementation of combination therapy. This is particularly important for cancer treatment that targets multiple biological pathways at the same time, as it can reduce the development of cancer cell resistance to single treatments. Calixarene can also be used as a carrier for contrast agents to help doctors more clearly observe the location and size of tumors before and after treatment. This application can not only improve the accuracy of diagnosis, but also monitor the distribution of drugs and tumor response in real time during treatment. Some calixarene derivatives have been shown to be able to regulate the functions of the immune system, such as activating or inhibiting specific immune cells, which may help improve the body's defense against tumors in cancer treatment. In these ways, calixarene provides multi-faceted support for anti-cancer therapy, from improving the targeting and therapeutic efficiency of drugs to improving diagnostic techniques and overcoming drug resistance. These research and application advances demonstrate the wide application potential of calixarene in modern medicine.

[0017] Necroptosis is a programmed cell death that, unlike apoptosis, involves swelling of the cell and rupture of the cell membrane, resulting in leakage of the cell contents into the surrounding environment. Necroptosis is considered a form of cell death between apoptosis (an orderly, non-inflammatory cell death) and necrosis (a disordered, inflammatory cell death).

[0018] Programmed necrosis is precisely regulated by specific signaling pathways, unlike the random necrosis process. It is usually activated when apoptosis is blocked, such as when apoptosis execution proteins (caspases) are inhibited. The key regulatory proteins of programmed necrosis include receptor interacting protein kinase 1 (RIPK1), RIPK3 and mixed lineage dynamin (MLKL). Activation of RIPK3 leads to phosphorylation of MLKL, which subsequently leads to the destruction of the cell membrane.

[0019] The regulation of programmed necrosis is associated with a variety of diseases, including neurodegenerative diseases, cardiovascular diseases, kidney diseases, and some types of cancer. The application of programmed necrosis in anti-cancer therapy focuses on its ability to bypass the drug resistance mechanisms of cancer cells, especially when cancer cells are resistant to traditional apoptosis-inducing chemotherapeutic drugs. In the clinic, understanding and utilizing the characteristics of programmed necrosis, especially its non-apoptotic death mechanism, provides a potential strategy to overcome the multidrug resistance of tumors and make anti-cancer treatment more diverse and effective. Future studies may further reveal the full picture of this pathway in anti-cancer therapy and may lead to the development of new treatment options. Summary of the invention

[0020] In order to solve the problems existing in the prior art, the present invention provides a host-guest complex and a preparation method thereof, as well as their application in the treatment of platinum-resistant ovarian cancer. The host compound and the guest compound are prepared by a specific method at a specific ratio to prepare a host-guest complex, and the prepared host-guest complex has the characteristics of being basically non-toxic to normal human cells, but being able to specifically kill platinum-resistant ovarian cancer. It is further found that the host-guest complex prepared by the present invention can overcome tumor resistance through the programmed necrosis pathway, achieve targeted treatment of resistant tumors or resistant cancers, and has good clinical application prospects.

[0021] To this end, the present invention adopts the following technical solutions:

[0022] In one aspect, the present invention provides a host-guest complex, characterized in that the host-guest complex consists of a host compound, a guest compound and a solvent;

[0023] Further, the host compound is a calixarene compound, the guest compound is a chemotherapeutic drug, and the solution is selected from one or more of PBS, DMSO or DMF;

[0024] Further, the molar concentration ratio of the host compound to the guest compound is 2:1 to 1:2;

[0025] Furthermore, the molar concentration ratio is 1:1.

[0026] In certain embodiments, the chemotherapeutic agent is selected from a DNA replication inhibitor;

[0027] In certain embodiments, the DNA replication inhibitor is selected from a DNA cross-linking agent;

[0028] In certain embodiments, the DNA cross-linking agent is selected from an alkylating agent;

[0029] In certain embodiments, the alkylating agent is selected from an organoplatinum compound;

[0030] In certain specific embodiments, the organoplatinum compound is selected from one or more of cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, and satraplatin;

[0031] In certain preferred embodiments, the organoplatinum compound is selected from cisplatin.

[0032] In certain embodiments, the calixarene compound is selected from one or more of calix[4]arene, calix[6]arene, calix[8]arene, 4-sulfonylcalix[4]arene, 4-sulfonylcalix[6]arene, and 4-sulfonylcalix[8]arene;

[0033] In certain specific embodiments, the calixarene compound is selected from one or more of 4-sulfonylcalix[4]arene, 4-sulfonylcalix[6]arene, and 4-sulfonylcalix[8]arene;

[0034] In certain preferred embodiments, the calixarene compound is selected from 4-sulfonylcalix[4]arene.

[0035] In certain particularly preferred embodiments, the host-guest complex is composed of a host compound selected from 4-sulfonylcalix[4]arene and a guest compound selected from cisplatin, in a molar concentration ratio of 1:1.

[0036] In another aspect, the present invention provides a method for preparing a host-guest complex, characterized in that it comprises the following steps:

[0037] ① Dissolving the host compound and the guest compound in a solvent respectively to prepare a host compound mother solution and a guest compound mother solution;

[0038] ② respectively diluting the main compound mother solution and the guest compound mother solution with a solvent to prepare a main compound working solution and a guest compound working solution;

[0039] ③ According to the molar concentration ratio of the host-guest complex formula, weigh the host compound working solution and the guest compound working solution respectively, place them in a reaction container, mix them evenly, heat and sonicate;

[0040] ④After ultrasound is completed, store and set aside.

[0041] In certain embodiments, the solution is selected from one or more of PBS, DMSO, or DMF.

[0042] In certain embodiments, the heating condition in step ③ is 30°C to 60°C, and the ultrasonic time is 15 to 45 minutes;

[0043] In certain specific embodiments, the heating condition is 40° C., and the ultrasonic time is 30 minutes.

[0044] In certain preferred embodiments, the method for preparing the host-guest complex comprises the following steps:

[0045] ① Dissolve the calixarene compound in PBS and the organoplatinum compound in DMSO to prepare a host compound mother solution and a guest compound mother solution;

[0046] ② respectively diluting the host compound mother solution and the guest compound mother solution with PBS to prepare the host compound working solution and the guest compound working solution solvent;

[0047] ③ Weigh the main compound working solution and the guest compound working solution respectively according to the molar concentration ratio of 2:1 to 1:2, place them in a reaction container, mix them evenly, heat at 30°C to 60°C, and ultrasonicate for 15 to 45 minutes;

[0048] ④After ultrasound is completed, store and keep aside.

[0049] In certain particularly preferred embodiments, the method for preparing the host-guest complex comprises the following steps:

[0050] ① Dissolve 4-sulfonylcalix[4]arene in PBS and cisplatin in DMSO to prepare a host compound mother solution and a guest compound mother solution;

[0051] ② Dilute the host compound mother solution and the guest compound mother solution with PBS to prepare the host compound working solution and the guest compound working solution respectively;

[0052] ③ Weigh the main compound working solution and the guest compound working solution in a molar concentration ratio of 1:1, place them in a reaction container, mix them evenly, heat at 40°C, and ultrasonicate for 30 minutes;

[0053] ④After ultrasound is completed, store and keep aside.

[0054] In other aspects, the present invention relates to a pharmaceutical composition for treating cancer, characterized in that the pharmaceutical composition is prepared from any host-guest complex described in the present invention, or a host-guest complex prepared by any preparation method described in the present invention;

[0055] In certain embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

[0056] In certain embodiments, the cancer is ovarian cancer;

[0057] In certain preferred embodiments, the ovarian cancer is platinum-resistant ovarian cancer;

[0058] In certain particularly preferred embodiments, the platinum-resistant ovarian cancer is cisplatin-resistant ovarian cancer.

[0059] In a fourth aspect, the present invention relates to use of any host-guest complex described in the present invention, or a host-guest complex prepared by any preparation method described in the present invention, or a pharmaceutical composition described in the present invention in the preparation of an anti-cancer drug;

[0060] In certain embodiments, the host-guest complex or pharmaceutical composition induces programmed necrosis in cancer cells by activating the RIPK1 / RIPK3 / MLKL signaling pathway;

[0061] In certain embodiments, the cancer is ovarian cancer;

[0062] In certain preferred embodiments, the ovarian cancer is platinum-resistant ovarian cancer;

[0063] In certain particularly preferred embodiments, the platinum-resistant ovarian cancer is cisplatin-resistant ovarian cancer;

[0064] In certain particularly specific preferred embodiments, the present invention relates to the use of any host-guest complex described in the present invention, or a host-guest complex prepared by any preparation method described in the present invention, or a pharmaceutical composition described in the present invention in the preparation of anti-cisplatin-resistant ovarian cancer drugs, wherein the host-guest complex or pharmaceutical composition induces programmed necrosis of cancer cells by activating the RIPK1 / RIPK3 / MLKL signaling pathway.

[0065] In a fifth aspect, the present invention relates to use of any host-guest complex described in the present invention, or a host-guest complex prepared by any preparation method described in the present invention, or a pharmaceutical composition described in the present invention in the preparation of an inducer of programmed necrosis of cancer cells;

[0066] In certain embodiments, the cancer cell programmed necrosis is induced by activation of the RIPK1 / RIPK3 / MLKL signaling pathway;

[0067] In certain embodiments, the cancer is ovarian cancer;

[0068] In certain preferred embodiments, the ovarian cancer is platinum-resistant ovarian cancer;

[0069] In certain particularly preferred embodiments, the platinum-resistant ovarian cancer is cisplatin-resistant ovarian cancer;

[0070] In certain particularly specific preferred embodiments, the present invention relates to the use of any host-guest complex described in the present invention, or a host-guest complex prepared by any preparation method described in the present invention, or a pharmaceutical composition described in the present invention in the preparation of an inducer of programmed necrosis of cisplatin-resistant ovarian cancer cells, wherein the programmed necrosis of the cancer cells is induced by activation of the RIPK1 / RIPK3 / MLKL signaling pathway.

[0071] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0072] The present invention prepares a host-guest complex by a specific method at a specific ratio of a host compound to a guest compound. The prepared host-guest complex is substantially non-toxic to normal human cells, but can specifically kill platinum-resistant ovarian cancer cells. It is further found that the host-guest complex prepared by the present invention can overcome tumor resistance caused by failure of apoptosis pathway through programmed necrosis pathway, achieve targeted treatment of drug-resistant tumors or drug-resistant cancers, and has good clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0073] Figure 1 Effects of DDP on the activities of different cells

[0074] Figure 2 . 4-Sulfonylcalixa[4]arene (SC4A) structure

[0075] Figure 3 Effects of different concentrations of SC4A on cell activity

[0076] Figure 4 Effects of SC4A-DDP complex on the activities of different cells

[0077] Figure 5 Effects of different SC4A-DDP complexes on cell activity

[0078] Figure 6 .Caspase3 / 7 activity in different cells

[0079] Figure 7 .RIPK1 / RIPK3 / MLKL protein expression

[0080] Figure 8 Effect of Nec-1s on cell viability DETAILED DESCRIPTION

[0081] The present invention is further described below in conjunction with specific examples. Unless otherwise specified, the raw materials, reagents or devices used in the following examples can be obtained from conventional commercial sources or can be obtained by existing known methods.

[0082] It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturers.

[0083] Example 1 Cell DDP sensitivity test

[0084] 1. Experimental samples

[0085] DDP was dissolved in DMSO to prepare a guest compound stock solution, which was then diluted with PBS to a guest compound working solution of appropriate concentration when used.

[0086] 2. Experimental Methods

[0087] MTT method:

[0088] Human ovarian cancer cells A2780 and OVCAR-8 were cultured in RPMI-1640 medium (containing 10% FBS, 1% PS) at 5% CO2 and 37°C.

[0089] Human ovarian cancer cisplatin-resistant cells A2780 / DDP and human ovarian cancer cisplatin-resistant cells OVCAR-8 / DDP were cultured in resistant RPMI-1640 medium (containing 10% FBS, 1% PS, 0.5 μg / mL DDP) at 5% CO2 and a constant temperature of 37°C.

[0090] The guest compound stock solution was prepared using PBS to prepare the guest compound working solution.

[0091] Collect cells (A2780, A2780 / DDP, OVCAR-8, OVCAR-8 / DDP) in logarithmic phase growth, adjust the concentration of cell suspension, inoculate the cell suspension in 96-well plates, and plate the cells to be tested to a density of about 10,000 / well, 100 μL cell suspension per well, replace all cells with RPMI-1640 medium without DDP, incubate at 5% CO2, 37°C for 24 hours, add 10 μL DDP to the culture plate, where the final concentrations of DDP are 33.3 μM, 10 μM, 3.33 μM, and 1 μM, respectively. Finally, add PBS as a blank control. Place the culture plate in a 5% CO2, 37°C constant temperature incubator for culture. After 24 hours, remove the culture plate, add 10 μl of MTT (5 mg / mL) solution to each well, continue to culture for 4 hours, terminate the culture, and carefully remove the culture solution in the well. Then, 100 μl of DMSO was added to each well, and the well was placed on a shaker and shaken at a low speed for 10 min to fully dissolve the purple crystals. The absorbance of each well was measured at 490 nm using an automatic microplate reader.

[0092] 3. Experimental results

[0093] The experimental results are as follows Figure 1 shown.

[0094] The results showed that A2780 and OVCAR-8 were sensitive to DDP, while A2780 / DDP and OVCAR-8 / DDP were moderately sensitive to DDP and had a certain degree of drug resistance.

[0095] Example 2 Screening of host compounds

[0096] 1. Experimental samples

[0097] After reading the literature, 4-sulfonyl calix[4]arene (SC4A, CAS: 112269-92-8) with good water solubility and low cytotoxicity was selected as the host compound to optimize the host-guest complex. The structural formula of SC4A is as follows: Figure 2 shown.

[0098] 2. Experimental Methods

[0099] MTT method:

[0100] Human normal liver cells LO2, human ovarian cancer cells A2780, and human ovarian cancer cells OVCAR-8 were cultured in RPMI-1640 medium (containing 10% FBS, 1% PS) at 5% CO2 and 37°C.

[0101] Human ovarian cancer cisplatin-resistant cells A2780 / DDP and human ovarian cancer cisplatin-resistant cells OVCAR-8 / DDP were cultured in resistant RPMI-1640 medium (containing 10% FBS, 1% PS, 0.5 μg / mL DDP) at 5% CO2 and a constant temperature of 37°C.

[0102] SC4A was dissolved in PBS to prepare the main compound stock solution.

[0103] Collect cells (LO2, A2780, A2780 / DDP, OVCAR-8, OVCAR-8 / DDP) in logarithmic phase growth, adjust the concentration of cell suspension, inoculate the cell suspension in a 96-well plate, and plate the cells to be tested to a density of about 10,000 / well. 100 μL of cell suspension per well was incubated at 5% CO2 and 37°C for 24 hours. 10 μL of SC4A was added to the culture plate, where the final concentrations of SC4A were 10 μM, 5 μM, 2.5 μM, 1.25 μM, and 0.625 μM, respectively. Finally, PBS was added as a blank control. The culture plate was placed in a 5% CO2, 37°C constant temperature incubator for culture. After 24 hours, the culture plate was removed, 10 μL of MTT (5 mg / mL) solution was added to each well, and the culture was continued for 4 hours. The culture was terminated and the culture solution in the well was carefully aspirated. Then, 100 μl of DMSO was added to each well, and the well was placed on a shaker and shaken at a low speed for 10 min to fully dissolve the purple crystals. The absorbance of each well was measured at 490 nm using an automatic microplate reader.

[0104] 3. Experimental results

[0105] The experimental results are as follows Figure 3 shown.

[0106] The results showed that SC4A had no inhibitory ability on four human ovarian cancer cells, A2780, A2780 / DDP, OVCAR-8, and OVCAR-8 / DDP, and had basically no toxicity to normal human liver cells LO2.

[0107] Example 3 Preparation of host-guest complex

[0108] 1. Experimental samples

[0109] The SC4A-DDP host-guest complex was prepared as follows:

[0110] ① Dissolve SC4A in PBS and DDP in DMSO to prepare the host compound mother solution and the guest compound mother solution;

[0111] ② Dilute the host compound mother solution and the guest compound mother solution with PBS to prepare 10 μM SC4A host compound working solution and 10 μM DDP guest compound working solution;

[0112] ③ According to the molar concentration ratio of 1:1, weigh 1 mL of the main compound SC4A main compound working solution and 1 mL of the guest compound working solution, place them in a 5 mL centrifuge tube in the reaction container, mix them evenly, place them in an ultrasonic instrument, and heat and ultrasonicate at 40°C for 30 minutes;

[0113] ④After ultrasound is completed, store and set aside.

[0114] In the SC4A-DDP prepared above, the DDP equivalent is 5 μM.

[0115] 2. Experimental Methods

[0116] MTT method:

[0117] Human ovarian cancer cells A2780 and OVCAR-8 were cultured in RPMI-1640 medium (containing 10% FBS, 1% PS) at 5% CO2 and 37°C.

[0118] Human ovarian cancer cisplatin-resistant cells A2780 / DDP and human ovarian cancer cisplatin-resistant cells OVCAR-8 were cultured in resistant RPMI-1640 medium (containing 10% FBS, 1% PS, 0.5 μg / mL DDP) at 5% CO2 and a constant temperature of 37°C.

[0119] Collect cells (A2780, A2780 / DDP, OVCAR-8, OVCAR-8 / DDP) in logarithmic phase growth, adjust the concentration of cell suspension, inoculate the cell suspension in 96-well plates, and plate the cells to be tested to a density of about 10,000 / well, 100 μL cell suspension per well, replace all cells with RPMI-1640 medium without DDP, incubate at 5% CO2, 37°C for 24 hours, observe under a microscope to observe cell adhesion growth, add 10 μL SC4A-DDP and 5 μM DDP to the culture plate, respectively. Finally, add PBS as a blank control. Place the culture plate in a 5% CO2, 37°C constant temperature incubator for culture. After 24 hours, remove the culture plate, add 10 μl of MTT (5 mg / mL) solution to each well, continue to culture for 4 hours, terminate the culture, and carefully remove the culture solution in the well. Then, 100 μl of DMSO was added to each well, and the well was placed on a shaker and shaken at a low speed for 10 min to fully dissolve the purple crystals. The absorbance of each well was measured at 490 nm using an automatic microplate reader.

[0120] 3. Experimental results

[0121] The experimental results are as follows Figure 4 shown.

[0122] The results showed that there was no significant difference in the killing ability of SC4A-DDP complex and DDP against non-resistant A2780 and OVCAR-8 cells; but for DDP-resistant A2780 / DDP and OVCAR-8 / DDP cells, the killing ability of SC4A-DDP complex was significantly higher than that of DDP at the same equivalent concentration.

[0123] Example 4 Screening of host-guest complexes

[0124] 1. Experimental samples

[0125] Prepare SC4A-DDP Control 1 as follows:

[0126] ① Dissolve SC4A in PBS and DDP in DMSO to prepare the host compound mother solution and the guest compound mother solution;

[0127] ② Dilute the host compound mother solution and the guest compound mother solution with PBS to prepare 10 μM SC4A host compound working solution and 10 μM DDP guest compound working solution;

[0128] ③ According to the molar concentration ratio of 1:1, weigh 1mL of the main compound SC4A main compound working solution and 1mL of the guest compound working solution, place them in a 5mL centrifuge tube in the reaction container, mix them evenly, place them in an ultrasonic instrument, and ultrasonicate them at room temperature for 30 minutes;

[0129] ④After ultrasound is completed, store and set aside.

[0130] Prepare SC4A-DDP Control 2 as follows:

[0131] ① Dissolve SC4A in PBS and DDP in DMSO to prepare the host compound mother solution and the guest compound mother solution;

[0132] ② Dilute the host compound mother solution and the guest compound mother solution with PBS to prepare 10 μM SC4A host compound working solution and 10 μM DDP guest compound working solution;

[0133] ③ According to the molar concentration ratio of 1:1, weigh 1 mL of the main compound SC4A main compound working solution and 1 mL of the guest compound working solution, place them in a 5 mL centrifuge tube in the reaction container, mix them evenly, and heat them at 40°C for 30 minutes;

[0134] ④After heating is completed, store and set aside.

[0135] Prepare SC4A-DDP Control 3 as follows:

[0136] ① Dissolve SC4A in PBS and DDP in DMSO to prepare the host compound mother solution and the guest compound mother solution;

[0137] ② Dilute the host compound mother solution and the guest compound mother solution with PBS to prepare 10 μM SC4A host compound working solution and 10 μM DDP guest compound working solution;

[0138] ③ According to the molar concentration ratio of 1:1, weigh 1mL of the main compound SC4A main compound working solution and 1mL of the guest compound working solution, place them in a 5mL centrifuge tube in the reaction container, mix them evenly, and leave them at room temperature for 30 minutes;

[0139] ④Store after 30 minutes and set aside.

[0140] In the SC4A-DDP, SC4A-DDP-1, SC4A-DDP-2 and SC4A-DDP-3 prepared above, the DDP equivalent is 5 μM.

[0141] 2. Experimental Methods

[0142] MTT method:

[0143] Human ovarian cancer cisplatin-resistant cells A2780 / DDP and human ovarian cancer cisplatin-resistant cells OVCAR-8 / DDP were cultured in resistant RPMI-1640 medium (containing 10% FBS, 1% PS, 0.5 μg / mL DDP) at 5% CO2 and a constant temperature of 37°C.

[0144] Collect cells (A2780 / DDP, OVCAR-8 / DDP) in logarithmic phase growth, adjust the concentration of cell suspension, inoculate the cell suspension in 96-well plates, and plate the cells to be tested to a density of about 10,000 / well, 100 μL cell suspension per well, replace all cells with RPMI-1640 medium without DDP, incubate at 5% CO2, 37°C for 24 hours, add 10 μL SC4A-DDP, SC4A-DDP-1, SC4A-DDP-2 and SC4A-DDP-3 to the culture plate, and add 5 μM DDP as a positive control. Finally, add PBS as a blank control. Place the culture plate in a 5% CO2, 37°C constant temperature incubator for culture. After 24 hours, remove the culture plate, add 10 μl of MTT (5 mg / mL) solution to each well, continue to culture for 4 hours, terminate the culture, and carefully remove the culture solution in the well. Then, 100 μl of DMSO was added to each well, and the well was placed on a shaker and shaken at a low speed for 10 min to fully dissolve the purple crystals. The absorbance of each well was measured at 490 nm using an automatic microplate reader.

[0145] 3. Experimental results

[0146] The experimental results are as follows Figure 5 shown.

[0147] The experimental results show that only SC4A-DDP prepared by heating and ultrasound can kill drug-resistant cells. Only heating, ultrasound or simple mixing cannot make SC4C and DDP form a host-guest complex that has a killing effect on drug-resistant cells.

[0148] Example 5 Study on the mechanism of host-guest complex killing drug-resistant cancer cells

[0149] DDP usually induces apoptosis of tumor cells, thereby producing anti-tumor activity. In order to explore whether SC4A-DDP also kills drug-resistant cells through apoptosis, the activity of Caspase 3 / 7 in cells treated with different drugs was detected.

[0150] Caspase 3 / 7 method:

[0151] Human normal liver cells LO2, human ovarian cancer cells A2780, and human ovarian cancer cells OVCAR-8 were cultured in RPMI-1640 medium (containing 10% FBS, 1% PS) at 5% CO2 and 37°C.

[0152] Human ovarian cancer cisplatin-resistant cells A2780 / DDP and human ovarian cancer cisplatin-resistant cells OVCAR-8 / DDP were cultured in resistant RPMI-1640 medium (containing 10% FBS, 1% PS, 0.5 μg / mL DDP) at 5% CO2 and a constant temperature of 37°C.

[0153] Collect cells (A2780, A2780 / DDP, OVCAR-8, OVCAR-8 / DDP) in logarithmic phase growth, adjust the concentration of cell suspension, inoculate the cell suspension in 96-well plates, and plate the cells to be tested to a density of about 10,000 / well, 100 μL of cell suspension per well, and replace all cells with RPMI-1640 medium without DDP, incubate at 5% CO2, 37°C for 24 hours, and add 10 μL of SC4A-DDP and DDP to the culture plate respectively. Finally, add PBS as a blank control. The culture plate was placed in a 5% CO2, 37°C constant temperature incubator for culture. After 24 hours, the culture plate was removed and the Caspase 3 / 7 activity was determined using the Caspase-Glo detection kit (Promega, Madison, Wisconsin, USA). Caspase 3 / 7 activity was then calculated according to the manufacturer's instructions.

[0154] The experimental results are as follows Figure 6 shown.

[0155] The experimental results show that the Caspase 3 / 7 activity of A2780 and OVCAR-8 was significantly enhanced after DDP treatment, indicating that DDP can induce apoptosis in non-resistant ovarian cancer cells. However, the Caspase 3 / 7 activity of resistant cells treated with DDP was not significantly enhanced, and the Caspase 3 / 7 activity of both resistant and non-resistant cells treated with SC4A-DDP complex was not significantly enhanced.

[0156] We further explored whether the SC4A-DDP complex kills drug-resistant cells by inducing other types of cell death.

[0157] Western blotting analysis

[0158] After SC4A-DDP and DDP treatment, proteins were extracted from cells using RIPA buffer (Thermo Scientific, Waltham, MA, USA) containing 1% PMSF and 1% protease and phosphatase inhibitor cocktail. After incubation on ice for 20 min, the supernatant was collected by centrifugation at 4°C and 15,000 rpm for 20 min. Then, the supernatant was purified by Pierce TM Protein concentration was quantified using Rapid Gold BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). 15 μg of protein was separated by SDS-PAGE and transferred to The membrane was then blocked with 5% skim milk in TBST for 60 min at room temperature. The membrane was probed with primary antibody (1:1000) overnight at 4°C. The membrane was washed three times with TBST for 15 min each time and incubated with secondary antibody (1:5000) for 60 min at room temperature. Afterwards, protein expression was exposed using ECL detection reagent (GE Healthcare, Buckinghamshire, UK) and detected using ChemiDoc TM Images were captured using the MP imaging system and Image Lab 5.1 software (Bio-Rad, Hercules, CA, USA).

[0159] The experimental results are as follows Figure 7 shown.

[0160] The experimental results show that after SC4A-DDP treats drug-resistant cells, it activates the RIPK1 / RIPK3 / MLKL signaling pathway, causing programmed necrosis of the cells and then killing the drug-resistant cells.

[0161] Furthermore, the cells were pretreated with the programmed necrosis specific inhibitor Nec-1s and then the SC4A-DDP complex was administered. It was found that Nec-1s reversed the killing effect of SC4A-DDP on drug-resistant cells (experimental results are shown in Figure 8 As shown), it was further confirmed that the SC4A-DDP complex kills drug-resistant tumor cells by inducing programmed necrosis of drug-resistant cells.

[0162] In summary, the host-guest complex prepared by the present invention can activate the RIPK1 / RIPK3 / MLKL signaling pathway, thereby inducing programmed necrosis, overcoming the failure of the cell apoptosis pathway to cause tumor resistance, and achieve targeted treatment of resistant tumors or resistant cancers, and has good clinical application prospects.

[0163] The above contents are further detailed descriptions of the present invention in combination with specific preferred embodiments, and it cannot be determined that the specific implementation of the present invention is limited to these descriptions. For ordinary technicians in the technical field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as falling within the protection scope of the present invention.

Claims

1. A host-guest complex, characterized in that: The host-guest complex is composed of a host compound, a guest compound and a solvent; The host compound is 4-sulfonylcalix[4]arene, the guest compound is cisplatin, and the solvent is PBS; The molar concentration ratio of the host compound to the guest compound is 1:1; The preparation method of the host-guest complex comprises the following steps: ① Dissolving the host compound and the guest compound in a solvent respectively to prepare a host compound mother solution and a guest compound mother solution; ② respectively diluting the main compound mother solution and the guest compound mother solution with a solvent to prepare a main compound working solution and a guest compound working solution; ③ According to the molar concentration ratio of the host-guest complex formula, weigh the host compound working solution and the guest compound working solution respectively, place them in a reaction container, mix them evenly, and ultrasonicate them at 40°C for 30 minutes; ④After ultrasound is completed, store and keep aside.

2. A pharmaceutical composition for treating cisplatin-resistant ovarian cancer, characterized in that: The pharmaceutical composition is prepared from the host-guest complex according to claim 1, and further comprises pharmaceutically acceptable excipients.

3. Use of the host-guest complex according to claim 1 or the pharmaceutical composition according to claim 2 in the preparation of a drug for treating cisplatin-resistant ovarian cancer.